News

Fierce Biotech13h
Merck wades deeper into HIV PrEP waters dominated by Gilead with 2 new late-stage trials
Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...
Connecticut Public3d
Penobscot County HIV outbreak continues to grow; providers say the rest of Maine is at risk
The Maine Center for Disease Control has identified two more positive HIV cases in Penobscot County, bringing the total cases ...
Duke HIV scientist searches for funding after Trump ends landmark vaccine center
In an interview with The News & Observer, Dr. Barton Haynes talks future of HIV vaccine development after HHS canceled the ...
Connecticut Public4d
UNAIDS report warns HIV progress at risk as U.S. funding cuts take hold
The UNAIDS annual report warns that Trump era HIV funding cuts could lead to 6 million more infections and 4 million deaths ...
Fred Hutchinson Cancer Center4d
Virologist and HIV expert Dr. Michael Emerman retires
During his 36-year career at Cancer Center, Michael Emerman, PhD, made fundamental discoveries about HIV, the retrovirus that causes AIDS. He co-founded the field of paleovirology and considers ...